ERK-dependent downregulation of Skp2 reduces Myc activity with hgf, leading to inhibition of cell proliferation through a decrease in Id1 expression

Molecular Cancer Research

Volumn 11, Issue 11, 2013, Pages 1437-1447

  Li, Xiaoran ^a   Bian, Ying ^a   Takizawa, Yuri ^a,b   Hashimoto, Tomio ^a   Ikoma, Toshiyuki ^a   Tanaka, Junzo ^a   Kitamura, Naomi ^a   Inagaki, Yutaka ^b   Komada, Masayuki ^a   Tanaka, Toshiaki ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA TUBULIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2;

ANIMAL EXPERIMENT; ARTICLE; CANCER PROGNOSIS; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LIVER NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-MYC; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84888251433     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0718     Document Type: Article

References (40)

1. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995;129:1177-80.
2. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metast Rev 2003;22:309-25.
3. Tajima H, Matsumoto K, Nakamura T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991;291:229-32.
4. Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci U S A 1992;89:373-7.
5. Furge KA, Zhang Y-W, Van de Woude GF. Metreceptor tyrosinekinase: enhanced signaling through adapter proteins. Oncogene 2000;19:5582-9.
6. Nakanishi K, Fujimoto J, Ueki T, Kishimoto K, Hashimoto-Tamaoki T, Furuyama J, et al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastas 1999;17:507-14.
7. Tsukada Y, Miyazawa K, Kitamura N. High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem 2001;276:40968-76.
8. Tsukada Y, Tanaka T, Miyazawa K, Kitamura N. Involvement of downregulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2. J Biochem 2004;136:701-9.
9. Han J, Tsukada Y, Hara E, Kitamura N, Tanaka T. Hepatocyte growth factor induces redistribution of p21 (CIP1) and p27 (KIP1) through ERK-dependent p16 (INK4a) up-regulation, leading to cell cycle arrest at G1 in HepG2 hepatoma cells. J Biol Chem 2005;280:31548-56.
10. Ushio K, Hashimoto T, Kitamura N, Tanaka T. Id1 is downregulated by hepatocyte growth factor via ERK-dependent and ERK-independent signaling pathways, leading to increased expression of p16Ink4a in hepatoma cells. Mol Cancer Res 2009;7:1179-88.
11. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002;416:703-9.
12. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins Skp2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008;8:438-49.
13. Carrano AC, Eytan E, Hershko A, Pagano M. Skp2 is required for the ubiquitin-mediated degradation of the Cdk-inhibitor p27. Nat Cell Biol 1999;1:193-9.
14. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Müller U, et al. p45/Skp2 promotes p27/Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
15. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slinger-land J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 2001;98:5043-8.
16. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A 2001;98:2515-20.
17. Oliveira AA, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003;21:722-7.
18. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003;11:1177-88.
19. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003;11:1189-200.
20. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, et al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 2010;12:457-67.
21. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. Myc inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
22. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009;69:2775-82.
23. Tanaka T, Kubota M, Shinohara K, Yasuda K, Kato J-Y. In vivo analysis of the cyclin D1 promoter during early embryogenesis in Xenopus. Cell Stuct Funct 2003;28:165-77.
24. Shirako E, Hirayama N, Tsukada Y, Tanaka T, Kitamura N. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor induced inhibition of HepG2 hepatoma cell proliferation. J Cell Biochem 2008;104:176-88.
25. Kondo A, Hirayama N, Sugito Y, Shono M, Tanaka T, Kitamura N. Coupling of Grb2 to Gab1 mediates hepatocyte growth factor-induced high lntensity ERK signalrequired for inhibition of HepG2 hepatoma cell proliferation. J Biol Chem 2008;283:1428-36.
26. Zhang H, Ozaki I, Mizuta T, Yoshimura T, Matsuhashi S, Hisatomi A, et al. Mechanism of beta 1-integrin-mediated hepatoma cell growth involves p27 and S-phase kinase-associated protein 2. Hepatology 2003;38:305-13.
27. Zhao Y, Jian W, Gao W, Zheng YX, Wang YK, Zhou ZQ, et al. RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell. Cancer Cell Int 2013;13:23.
28. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-97.
29. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-99.
30. Swarbrick A, Akerfeldt MC, Lee CS, Sergio CM, Caldon CE, Hunter LJ, et al. Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene 2005;24:381-9.
31. Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, et al. Id1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res 2010;70:3239-48.
32. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:318-30.
33. Zeller KI, Zhao XD, Lee CWH, Chiu KP, Yao F, Yustein JT, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 2006;103:17834-9.
34. Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007;67:4149-56.
35. Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 2009;8:3455-61.
36. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989;4:715-24.
37. Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of cmyc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 1993;53:1719-23.
38. Saddic LA, Wirt S, Vogel H, Felsher DW, Sage J. Functional interactions between retinoblastoma and c-Myc in a mouse model of hepatocellular carcinoma. PLos ONE 2011;6:e19758.
39. Zimonjic DB, Popescu NC. Role of Dlc1 tumor suppressor gene and Myc oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics. Int J Oncol 2012;41:393-406.
40. Santoni-Rugiu E, Preisegger KH, Kiss A, Audolfsson T, Shiota G, Schmidt EV, et al. Thorgeirsson S. S. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci U S A 1996;93:9577-82.